PLYGF (PolyPeptide Group AG) Other Current Receivables: $4.0 Mil (As of Dec. 2025)


PLYGF PolyPeptide Group AG PLYGF
56 GF Score
Price $43.00
GF Value $40.45
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is PolyPeptide Group AG Other Current Receivables?

PolyPeptide Group AG PLYGF 56 Other Current Receivables is $4.0 Mil as of Dec. 2025. GuruFocus rates PLYGF with a GF Score™ of 56/100 and a GF Value™ of $40.45 (Fairly Valued). The stock has 8 warning signs investors should review.

PolyPeptide Group AG's Other Current Receivables for the quarter that ended in Dec. 2025 was $4.0 Mil.

PolyPeptide Group AG's quarterly Other Current Receivables declined from Dec. 2024 ($3.94 Mil) to Jun. 2025 ($3.36 Mil) but then increased from Jun. 2025 ($3.36 Mil) to Dec. 2025 ($4.03 Mil).

PolyPeptide Group AG's annual Other Current Receivables increased from Dec. 2023 ($2.29 Mil) to Dec. 2024 ($3.94 Mil) and increased from Dec. 2024 ($3.94 Mil) to Dec. 2025 ($4.03 Mil).

PolyPeptide Group AG Other Current Receivables Related Terms

PolyPeptide Group AG Other Current Receivables Historical Data

* Premium members only.

The historical data trend for PolyPeptide Group AG's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PolyPeptide Group AG Other Current Receivables Chart

PolyPeptide Group AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial 2.89 2.82 2.29 3.94 4.03

PolyPeptide Group AG Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.29 12.31 3.94 3.36 4.03
PLYGF
56GF Score
PolyPeptide Group AG PLYGF
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PolyPeptide Group AG Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $4.0 Mil mean?
PolyPeptide Group AG (PLYGF) has a Other Current Receivables of $4.0 Mil as of Dec. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on PolyPeptide Group AG and its competitors.
Is PolyPeptide Group AG's Other Current Receivables too high?
PolyPeptide Group AG's current Other Current Receivables is $4.0 Mil. Overall, PolyPeptide Group AG has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PolyPeptide Group AG's Other Current Receivables compare to ZTS and UTHR?
PolyPeptide Group AG's Other Current Receivables of $4.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on PolyPeptide Group AG and its competitors. PolyPeptide Group AG's current Other Current Receivables is $4.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PolyPeptide Group AG stock overvalued right now?
Based on GuruFocus' analysis, PolyPeptide Group AG (PLYGF) is currently considered Fairly Valued. The stock's GF Value™ is $40.45, compared to a current price of $43.00 — trading 6.3% above its estimated fair value. The current Other Current Receivables is $4.0 Mil. PolyPeptide Group AG's overall GF Score™ is 56/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For PolyPeptide Group AG (PLYGF), the current Other Current Receivables is $4.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PolyPeptide Group AG (PLYGF) Overvalued in 2026?

Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued. The current stock price of $43.00 is trading 6.3% above its estimated GF Value™ of $40.45. GuruFocus considers PolyPeptide Group AG to be Fairly Valued.

Key valuation signals for PLYGF:

  • Other Current Receivables: $4.0 Mil
  • GF Value™: $40.45 vs. price of $43.00 (6.3% above fair value)
  • GF Score™: 56/100 with 8 warning signs

No single metric tells the full story. See the PLYGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PolyPeptide Group AG Business Description

Address Neuhofstrasse 24, Baar, Zug, CHE, 6340
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
56GF Score

Get the complete analysis for PLYGF

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$43.00
Price
$40.45
GF Value